Athersys Inc (ATHX.OQ) Key Developments | Reuters.com
Edition:
United States

Athersys Inc (ATHX.OQ)

ATHX.OQ on NASDAQ Stock Exchange Capital Market

2.17USD
4:00pm EDT
Change (% chg)

$0.05 (+2.36%)
Prev Close
$2.12
Open
$2.12
Day's High
$2.18
Day's Low
$2.08
Volume
127,480
Avg. Vol
174,476
52-wk High
$2.89
52-wk Low
$0.94

Latest Key Developments (Source: Significant Developments)

HEALIOS and Athersys sign licensing contract
Friday, 8 Jan 2016 01:00am EST 

HEALIOS K.K:Signed licensing contract with Athersys, on MultiStem.To pay $15 mln upfront to Athersys and sees to pay up to $30 mln in total as milestone payments.  Full Article

Athersys Inc updates on development strategy in Japan
Wednesday, 21 Oct 2015 06:30am EDT 

Athersys Inc:Says Co and Chugai Pharmaceutical Co., Ltd have ended license agreement between them for exclusive development and commercialization of MultiStem cell therapy for ischemic stroke in Japan.Parties were unable to reach an agreement on the modification of the financial terms of the agreement and on development strategy in Japan, in light of the results from the Phase 2 clinical study.All rights will revert to Athersys, and Athersys will retain the $10 million license fee paid by Chugai.  Full Article

Athersys announces results from phase 2 study for treatment of ischemic stroke
Friday, 17 Apr 2015 05:59am EDT 

Athersys, Inc:Announced interim results from phase 2 clinical study of intravenous administration of MultiStem cell therapy to treat patients who suffered an ischemic stroke.Study results demonstrate favorable safety and tolerability consistent with prior studies.  Full Article

Athersys Inc and Chugai Pharmaceutical Co Ltd enter license agreement and collaboration to develop MultiStem Cell Therapy
Monday, 2 Mar 2015 06:00am EST 

Athersys Inc and Chugai Pharmaceutical Co Ltd:Says a partnership and license agreement to exclusively develop and commercialize MultiStem cell therapy for ischemic stroke in Japan.Ischemic stroke represents a priority disease area in Japan, given the high healthcare burden of the condition and the expected increase in incidence associated with Japan's aging population.  Full Article